Skip to main content
SpringerLink
Log in

Psoriasis and Comorbidities

  • Chapter
  • First Online:
Advances in Psoriasis

Abstract

Emerging evidence demonstrates that patients with psoriasis are more likely to suffer from hypertension, dyslipidaemia, obesity, diabetes, cardiovascular disease, stroke and atrial fibrillation. The relationship between psoriasis and these diseases is complicated by multiple confounder variables including diet, exercise, alcohol and smoking which differ between the general population and patients with psoriasis. Psoriasis is a disease of chronic systemic inflammation and it is increasingly clear that inflammation plays a pivotal role in the pathogenesis of cardiovascular disease, hypertension, diabetes and obesity. This provides a mechanism by which psoriasis may confer an additional risk of these comorbidities.

Patients with psoriasis are also at an increased risk of experiencing psychiatric illness (particularly depression) and malignancy. The nature of this relationship remains to be determined. Genome wide association studies have identified that patients with psoriasis have an increased risk of developing diseases associated with immune dysfunction (e.g. ulcerative colitis) and autoimmune disease (e.g. type 1 diabetes).

Recognition of comorbid disease is of great importance as this may affect treatment choice, treatment efficacy, morbidity and mortality.

Conflict of Interest

P.M.L. has received a travel grant from Janssen-Cilag and Abbot.

H.S.Y. has acted as a consultant or speaker to Abbott, Amgen, Biogen-Idec, Galderma, Janssen-Cilag, Leo-Pharma, Lily, Novartis, Schering-Plough, Stiefel, and Wyeth/Pfizer.

R.B.W. has acted as a consultant or speaker to Abbott, Janssen-Cilag, Leo-Pharma, Merck-Serono, Novartis, Schering-Plough and Wyeth.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lawlor DA, Lean M, Sattar N. ABC of obesity: obesity and vascular disease. Br Med J. 2006;333(7577):1060–3.

    Google Scholar 

  2. McMillan DC, Sattar N, McArdle CS. ABC of obesity. Obesity and cancer. Br Med J. 2006;333(7578): 1109–11.

    Google Scholar 

  3. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356(3):213–5.

    CAS  PubMed  Google Scholar 

  4. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172(6):298–304.

    CAS  PubMed  Google Scholar 

  5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–6.

    CAS  PubMed  Google Scholar 

  6. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.

    PubMed  Google Scholar 

  7. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–5.

    CAS  PubMed  Google Scholar 

  8. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902.

    CAS  PubMed  Google Scholar 

  9. Shapiro J, Cohen AD, Weitzman D, Tal R, David M. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol. 2012;66(2):252–8.

    PubMed  Google Scholar 

  10. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.

    PubMed  Google Scholar 

  11. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–65.

    PubMed  Google Scholar 

  12. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–62.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585–9.

    CAS  PubMed  Google Scholar 

  14. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–34.

    PubMed  Google Scholar 

  15. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76–85.

    PubMed  Google Scholar 

  16. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167(15):1670–5.

    PubMed  Google Scholar 

  17. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–7.

    CAS  PubMed  Google Scholar 

  18. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–96.

    CAS  PubMed  Google Scholar 

  19. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8(1):1–12.

    PubMed  Google Scholar 

  20. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.

    CAS  PubMed  Google Scholar 

  22. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care. 2004;27(7):1699–705.

    PubMed  Google Scholar 

  23. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–73.

    CAS  PubMed  Google Scholar 

  24. de Menezes Ettinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg. 2006;16(1):94–7.

    PubMed  Google Scholar 

  25. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20(2):81–7.

    CAS  PubMed  Google Scholar 

  26. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–7.

    PubMed  Google Scholar 

  27. Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–7.

    PubMed  Google Scholar 

  28. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association Studies sor Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636–47.

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Li W, Man XY. Linear psoriasis. CMAJ. 2012;184(7):789.

    PubMed Central  PubMed  Google Scholar 

  30. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217(4):365–73.

    PubMed  Google Scholar 

  31. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–75.

    CAS  PubMed  Google Scholar 

  32. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.

    CAS  PubMed  Google Scholar 

  33. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–6.

    PubMed  Google Scholar 

  34. Menter A, Gordon K, Goldblum O, Gu Y. Efficacy and safety of adalilmumab are consistent across weight quartiles in patients with moderate to severe psoriasis: subanalysis of REVEAL. J Am Acad Dermatol. 2009;54(Suppl):S101–11.

    Google Scholar 

  35. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–11.

    PubMed  Google Scholar 

  36. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.

    CAS  PubMed  Google Scholar 

  37. Laws PM, Downs AM, Parslew R, et al. Practical experience of Ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol. 2012;166(1):189–95.

    CAS  PubMed  Google Scholar 

  38. Wu JJ, Channual JC, Dann F. Association of systemic psoriasis therapies and incidence of myocardial infarction. Br J Dermatol. 2012;166(1):232, author reply 233.

    CAS  PubMed  Google Scholar 

  39. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008;88(6):561–5.

    CAS  PubMed  Google Scholar 

  40. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.

    PubMed  Google Scholar 

  41. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5):1037–43.

    PubMed  Google Scholar 

  42. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7(4):373–7.

    PubMed  Google Scholar 

  43. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42.

    PubMed Central  PubMed  Google Scholar 

  44. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.

    CAS  PubMed  Google Scholar 

  45. Kimball AB, Robinson Jr D, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217(1):27–37.

    CAS  PubMed  Google Scholar 

  46. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24 Suppl 2:23–30.

    PubMed  Google Scholar 

  47. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–21.

    PubMed  Google Scholar 

  48. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.

    PubMed  Google Scholar 

  49. Wan J, Abuabara K, Troxel AB, et al. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol. 2012;66(3):376–86.

    PubMed Central  PubMed  Google Scholar 

  50. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190(1):1–9.

    CAS  PubMed  Google Scholar 

  52. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199–205.

    CAS  PubMed  Google Scholar 

  53. Ryder KW, Epinette WW, Jay SJ, Ransburg RC, Glick MR. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chim Acta. 1985;153(2):143–6.

    CAS  PubMed  Google Scholar 

  54. Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol. 1998;78(1):22–6.

    CAS  PubMed  Google Scholar 

  55. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115(5):141–50.

    CAS  Google Scholar 

  56. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–64.

    CAS  PubMed  Google Scholar 

  57. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778–86.

    CAS  PubMed  Google Scholar 

  58. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25(4):383–91.

    CAS  PubMed  Google Scholar 

  59. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005;2:29.

    Google Scholar 

  60. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644–50.

    PubMed  Google Scholar 

  61. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res. 2012;304(2):119–25.

    PubMed  Google Scholar 

  62. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157(6):1249–51.

    CAS  PubMed  Google Scholar 

  63. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25(10):1187–93.

    CAS  PubMed  Google Scholar 

  64. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008;45(2):114–6.

    CAS  PubMed  Google Scholar 

  65. Warren RB, Smith RL, Flynn E, et al. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol. 2011;164(3):660–4.

    CAS  PubMed  Google Scholar 

  66. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol. 2008;58(3):421–9.

    PubMed  Google Scholar 

  67. Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol. 2011;65(1):77–83.

    PubMed  Google Scholar 

  68. Chang YC, Wu WM, Hsu LA. Lack of association between the genetic variations in the C-reactive protein gene and the risk of psoriasis among the Taiwanese. Mol Biol Rep. 2012;39(4):4111–7.

    CAS  PubMed  Google Scholar 

  69. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28.

    CAS  PubMed  Google Scholar 

  70. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation. 2007;115(13):1806–10; discussion 1811.

    PubMed  Google Scholar 

  71. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.

    Google Scholar 

  72. Balkau B, Eschwege E. Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obes Metab. 1999;1 Suppl 1:S23–31.

    PubMed  Google Scholar 

  73. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):575–94, ix.

    PubMed  Google Scholar 

  74. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.

    PubMed  Google Scholar 

  75. Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551–6.

    PubMed  Google Scholar 

  76. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.

    CAS  PubMed  Google Scholar 

  77. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.

    PubMed  Google Scholar 

  78. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066–76.

    PubMed  Google Scholar 

  79. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68–73.

    CAS  PubMed  Google Scholar 

  80. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–8.

    PubMed  Google Scholar 

  81. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37(2):146–55.

    PubMed  Google Scholar 

  82. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23(2):137–43.

    PubMed  Google Scholar 

  83. Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R, Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2012;165(3):670–82.

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–7.

    CAS  PubMed  Google Scholar 

  85. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159(4):820–6.

    CAS  PubMed  Google Scholar 

  86. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158(5):1134–5.

    CAS  PubMed  Google Scholar 

  87. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17(8):699–706.

    PubMed  Google Scholar 

  88. Women’s high CRP levels can predict hypertension. Healthcare Benchmarks Qual Improv. 2004;11(2):20–1.

    Google Scholar 

  89. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65.

    CAS  PubMed  Google Scholar 

  90. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb. 2009;29(3):424–30.

    CAS  Google Scholar 

  91. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.

    CAS  PubMed  Google Scholar 

  92. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

    CAS  PubMed  Google Scholar 

  93. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99(5):469–75.

    CAS  PubMed  Google Scholar 

  94. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102(6):14S–8.

    CAS  PubMed  Google Scholar 

  95. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135(12):1490–3.

    CAS  PubMed  Google Scholar 

  96. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225–30.

    PubMed  Google Scholar 

  97. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–6.

    Google Scholar 

  98. Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16):2054–64.

    PubMed  Google Scholar 

  99. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–3.

    PubMed  Google Scholar 

  100. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6.

    PubMed Central  PubMed  Google Scholar 

  102. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–57.

    CAS  PubMed  Google Scholar 

  103. Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the UK: a 9 year Experience of Infusion Reactions at a Single Centre. Br J Dermatol. 2012;167(2):411–6.

    CAS  PubMed  Google Scholar 

  104. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010;130(4):962–7.

    CAS  PubMed  Google Scholar 

  105. Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol. 2011;131(5):1159–66.

    CAS  PubMed  Google Scholar 

  106. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009;160(5):1048–56.

    CAS  PubMed  Google Scholar 

  107. Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol. 2010;130(4):917–9.

    CAS  PubMed  Google Scholar 

  108. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol. 2010;130(4):919–22.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol. 2011;131(5):1007–10.

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Friedewald Jr VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101(8):1119–26.

    PubMed  Google Scholar 

  111. Boehncke S, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303(6):381–8.

    CAS  PubMed  Google Scholar 

  112. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol. 1998;134(12):1582–5.

    CAS  PubMed  Google Scholar 

  113. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–5.

    CAS  PubMed  Google Scholar 

  114. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–201.

    CAS  PubMed  Google Scholar 

  115. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129(11):2604–12.

    CAS  PubMed  Google Scholar 

  116. Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84–91.

    PubMed  Google Scholar 

  117. Prizment AE, Alonso A, Folsom AR, et al. Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study. Cancer Causes Control. 2011;22(7):1003–10.

    PubMed Central  PubMed  Google Scholar 

  118. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10–5.

    CAS  PubMed  Google Scholar 

  119. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4(3):e1000041.

    PubMed Central  PubMed  Google Scholar 

  120. Ni A, Chen H, Wu Y, Li W, Chen S, Li J. Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci. 2012;32(2):287–90.

    CAS  PubMed  Google Scholar 

  121. Hughes S, Williams SE, Turnberg LA. Crohn’s disease and psoriasis. N Engl J Med. 1983;308(2):101.

    CAS  PubMed  Google Scholar 

  122. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol. 1982;106(3):323–30.

    CAS  PubMed  Google Scholar 

  123. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990;85(8):962–3.

    CAS  PubMed  Google Scholar 

  124. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet. 1999;64(3):808–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  125. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6(8):1349–56.

    CAS  PubMed  Google Scholar 

  126. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199–204.

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–90.

    CAS  PubMed Central  PubMed  Google Scholar 

  128. Rapp SR, Feldman SR, Exum ML, Fleischer Jr AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7.

    CAS  PubMed  Google Scholar 

  129. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–7.

    PubMed  Google Scholar 

  130. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–4.

    CAS  PubMed  Google Scholar 

  131. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–50.

    CAS  PubMed  Google Scholar 

  132. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10.

    CAS  PubMed  Google Scholar 

  133. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.

    CAS  PubMed  Google Scholar 

  134. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.

    PubMed Central  PubMed  Google Scholar 

  135. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7(10):1107–14.

    CAS  PubMed  Google Scholar 

  136. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

    CAS  PubMed  Google Scholar 

  137. Kleyn CE, McKie S, Ross AR, et al. Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol. 2009;129(11):2613–9.

    CAS  PubMed  Google Scholar 

  138. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

    CAS  PubMed  Google Scholar 

  139. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010;90(1):23–6.

    PubMed  Google Scholar 

  140. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379–82.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Chapel Allerton Hospital, The University of Leeds, Chapeltown Road Leeds, West Yorkshire, LS7 4SA, UK

    Philip M. Laws

  2. Department of Dermatology, The Dermatology Centre, Salford Royal NHS Foundation Trust, Irving Building, Manchester, M6 8HD, UK

    Richard B. Warren BSc (Hons), MBChB (Hons), PhD

  3. Department of Dermatology, Manchester Academic Health Science Centre, Salford Royal Hospital, The University of Manchester, Scott Lane, Salford, Manchester, M6 8HD, UK

    Helen S. Young MB, ChB, PhD, MRCP (UK)

Authors
  1. Philip M. Laws
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen S. Young MB, ChB, PhD, MRCP (UK)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard B. Warren BSc (Hons), MBChB (Hons), PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip M. Laws .

Editor information

Editors and Affiliations

  1. St. Luke's -Roosevelt Hospital Center, New York, New York, USA

    Jeffrey M. Weinberg

  2. Department of Dermatology, Icahn School of Medicine, New York, New York, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Laws, P.M., Young, H.S., Warren, R.B. (2014). Psoriasis and Comorbidities. In: Weinberg, J., Lebwohl, M. (eds) Advances in Psoriasis. Springer, London. https://doi.org/10.1007/978-1-4471-4432-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4432-8_21

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4431-1

  • Online ISBN: 978-1-4471-4432-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation